Research programme: anticancer monoclonal antibodies - AIMM Therapeutics

Drug Profile

Research programme: anticancer monoclonal antibodies - AIMM Therapeutics

Alternative Names: AT 1331; AT 1412; AT 1413; AT 1628; AT 1630; AT 1636

Latest Information Update: 11 May 2017

Price : $50

At a glance

  • Originator AIMM Therapeutics
  • Class Monoclonal antibodies
  • Mechanism of Action CD antigen modulators; CD9 antigen modulators; Ribonucleoprotein modulators; RNA helicase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Acute myeloid leukaemia; Colorectal cancer; Malignant melanoma; Multiple myeloma
  • Research Liver cancer; Solid tumours

Most Recent Events

  • 26 Apr 2017 Early research in Liver cancer in Netherlands (Parenteral) (AIMM Therapeutics pipeline, April 2017)
  • 26 Apr 2017 Early research in Solid tumours in Netherlands (Parenteral) (AIMM Therapeutics pipeline, April 2017)
  • 26 Apr 2017 Preclinical for Malignant melanoma in Netherlands (Parenteral) (AIMM Therapeutics pipeline, April 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top